Modular Solution for Cosmetics Compliance
Checking the Conformity of your Formulas
Compliance of your Regulatory Files
Flexible Software Solution for Product Compliance
Regulatory Monitoring Tool
Platform for the Traceability of Risky Substances
Software for Creating and Managing SDS
Software for managing your chemical risk
Worldwide Compliance for your Cosmetics, Fragrances & Skincare Products
U.S. cosmetics compliance
Compliance of your Food Supplements
Regulatory Services for Chemicals in Europe
Support for Authorization Files
Register your Chemical Substances in Europe
Customized Regulatory Monitoring of your Substances
Biocides Product Compliance
Marketing Authorization for Biocides
Collaborative Approach to Biocides Marketing Authorization
Regulatory Monitoring of Biocides
Support for your Safety Data Sheets
A recent study published in Frontiers in Toxicology assessed the application of the essential use concept to substances of very high concern (SVHCs) under the REACH.
Recevez une fois par mois les dernières actus réglementaires et conseils d’experts.
In January 2022, four new substances were added to the Candidate List for authorization, including the first cosmetic-related endocrine disruptor. This update highlights the European Commission's focus on substances posing significant health and environmental risks.
Learn about the sustainable development goals for post-2015, focusing on chemical and waste management. Find out how the UN Environment Program is addressing these issues and the importance of clear goals in this area for sustainable development policies.
Deputy Commissioner Michael Taylor of the FDA expresses disappointment at lack of compromise in updating regulations for cosmetic ingredients, potentially harming American consumers. Industry groups refute claims, highlighting the need for regulation in a largely self-regulated industry.
The Australian National Industrial Chemicals Notification Scheme has proposed banning phthalate DMEP in cosmetics due to potential health risks. Although not currently used in Australia, DMEP could enter the market as a substitute for other restricted phthalates.
The challenges and proposed improvements for a new regulatory bill, highlighting issues with current substance monitoring protocols and deadlines. Suggestions include clearer language, prioritization of substances, and detailed agency deadlines, though concerns about feasibility remain.
ANSES has identified five priority substances, including two endocrine disruptors, in a recent study. The report highlights the need for further research and potential substitution of these substances due to their reproductive toxicity and exposure risks.
